INTRODUCTION
============

Globally, an estimated 34 million people were infected with human immunodeficiency (HIV) at the end of 2011. In Korea, after the first case of HIV infection was reported in 1985, the number of cumulative HIV survivors rose to approximately 7,000 at the end of 2011, although the overall prevalence in the population was very low (\< 1%) \[[@b1-kjim-2014-322]\]. HIV infection leads to immunosuppression, which can result in life-threatening opportunistic diseases (ODs). Combination antiretroviral therapy reduced the mortality and morbidity \[[@b2-kjim-2014-322],[@b3-kjim-2014-322]\], but despite advances in antiretroviral therapy, ODs remain one of the main causes of morbidity and mortality in HIV/AIDS patients.

The frequencies of ODs may vary across countries because of differences in genetic, environmental, and social backgrounds. Two studies have examined the epidemiology and clinical manifestations of ODs in Korean patients with HIV/AIDS \[[@b4-kjim-2014-322],[@b5-kjim-2014-322]\]. The introduction of combination antiretroviral therapy and the use of prophylactic antimicrobials for ODs have changed the prevalence of ODs over time. Consequently, an understanding of the current epidemiology of ODs among HIV/AIDS patients should help to establish guidelines for the prevention of ODs. This study evaluated the prevalence of ODs among HIV-infected patients in the era of highly active antiretroviral therapy, and the risk factors associated with ODs.

METHODS
=======

Study design and time period
----------------------------

The cohort recruited patients older than 18 years infected with HIV after obtaining informed consent. Trained researchers from all centers prospectively collected information every 6 months, using a standardized protocol. The information included the medical history, socioeconomic status, physical findings, laboratory findings including immunological and virological status, and ODs. In this study, we determined the prevalence of ODs using the baseline data of the HIV/AIDS cohort study at the time of enrollment, from December 2006 to July 2013.

Definition
----------

ODs were diagnosed from the clinical, laboratory, and pathology findings, following published criteria \[[@b6-kjim-2014-322]\]. A diagnosis of tuberculosis (TB) was based on compatible symptoms/signs and positive acid-fast bacilli (AFB) smear, culture, polymerase chain reaction (PCR), and histological or radiological findings compatible with TB. Disseminated TB was defined when more than two sites were involved \[[@b7-kjim-2014-322]\]. *Pneumocystis jirovecii* pneumonia was confirmed based on compatible symptoms/signs, and radiological findings such as bilateral, diffuse interstitial infiltrates, demonstration of the cyst wall on methenamine silver staining, or a positive *P. jirovecii* PCR. Cytomegalovirus (CMV) viremia was detected using a CMV PCR assay. CMV retinitis was diagnosed by an ophthalmologist. CMV disease such as pneumonia or hepatitis was diagnosed based on compatible symptoms and pathology staining for CMV.

Ethics approval
---------------

Ethics approval was obtained from all participating hospitals.

Data analysis
-------------

Data are provided as mean ± standard deviation, or as proportions. Student *t* test or the Mann-Whitney *U* test was used to analyze continuous variables, and the chi-square test or Fisher exact test was used for categorical variables. We analyzed the risk factors associated with developing ODs in HIV-infected patients using both univariate and multivariate logistic regression analyses. Variables with a *p* value \< 0.1 in the univariate analysis were added in a forward stepwise manner and selected to create the final model for multivariate analysis with forward variables. Data were analyzed using the SPSS version 16.0 (SPSS Inc., Chicago, IL, USA), and a *p* \< 0.05 was considered statistically significant.

RESULTS
=======

The study enrolled 1,086 HIV-infected patients (1,007 males and 79 females; median age, 41 years) at 19 university hospitals from 2006 to 2012 ([Table 1](#t1-kjim-2014-322){ref-type="table"}). The majority of patients (n = 601, 55.4%) were 30 to 50 years of age. The median CD4 T cell count at enrollment was 352 cells/mm^3^ (interquartile range \[IQR\], 207 to 514), and 22.9% of the patients (n = 206) had fewer than 200 cells/mm^3^. The median viral load at enrollment was 5.69 log copies/mL (IQR, 3.88 to 6.24),while 53.2% of the patients had undetectable viral loads. At enrollment, 76% of the patients (n = 355) were receiving antiretroviral agents ([Table 1](#t1-kjim-2014-322){ref-type="table"}).

Opportunistic diseases
----------------------

Among the 1,086 HIV-infected patients, 613 ODs developed in 297 patients (24.4%), a rate of 2.1 episodes/patient. [Table 2](#t2-kjim-2014-322){ref-type="table"} summarizes the ODs seen in our study. Candidiasis was the most prevalent OD (n = 176, 16.2%), and was mainly oral candidiasis (n = 120), followed by esophageal candidiasis (n = 54). TB was the second most frequent OD (n = 120, 11.0%). Among the patients with TB, 28.3% (n = 34) were taking antiretroviral treatment and 54.2% (n = 65), 15.8% (n = 19), and 15% (n = 18) had pulmonary, lymph node, and disseminated TB, respectively. The main diagnostic method for TB was the AFB smear (n = 58, 48.3%), followed by AFB culture (n = 49, 49%), PCR (n = 28, 23.3%), and pathology (n = 20, 16.6%). Based on clinical and radiological characteristics, anti-TB medication was given empirically to three patients with negative results on a routine test for TB. Of the 19 patients who had antimicrobial drug resistance tests, 26.3% (n = 5) were resistant to isoniazid, 15.8% (n = 3) to rifampin, and 10.5% (n = 2) to ethambutol. *P. jirovecii* pneumonia (n = 121, 11.1%) was the third most common OD, followed by CMV infection (n = 52, 4.7%), and herpes zoster (n = 44, 4.0%). CMV retinitis was found in 19 patients. The prevalence rates of Kaposi's sarcoma (n = 8, 0.7%) and toxoplasmosis (n = 4, 0.4%) were low.

The median CD4 T cell count was 49 cells/mm^3^ (IQR, 17 to 133) in patients with esophageal candidiasis, 30 cells/mm^3^ (IQR, 11 to 68) in *P. jirovecii* pneumonia cases, and 87 cells/mm^3^ (IQR, 37 to 205) in TB cases ([Table 2](#t2-kjim-2014-322){ref-type="table"}). When patients were first diagnosed with HIV, 13.9% (n = 151) had AIDS-defining illnesses. The most prevalent indicator of AIDS was *P. jirovecii* pneumonia (n = 91, 60.3%), followed by *Mycobacterium tuberculosis* infection (n = 69, 45.6%) and esophageal candidiasis (n = 38, 25.2%).

[Fig. 1](#f1-kjim-2014-322){ref-type="fig"} shows the distribution of the CD4 cell count in study patients with OD. Patients who had a CD4 T cell count less than 50 cells/mm^3^ had a high prevalence of *P. jirovecii* pneumonia (66.9%), CMV infection (56.2%), or esophageal or respiratory candidiasis (56.3%). A high prevalence of TB (73.8%) was found in patients with a CD4 T cell count less than 200 cells/mm^3^.

Risk factors for opportunistic diseases
---------------------------------------

[Table 1](#t1-kjim-2014-322){ref-type="table"} compares the demographic characteristics of patients with and without ODs. There were no differences in sex, transmission route, viral load, or body mass index. Patients with ODs were significantly older than patients without ODs (median, 44; IQR, 36 to 52 years vs. median, 41; IQR, 32 to 50 years; *p* \< 0.01), and had a lower CD4 T cell count at the time of HIV diagnosis (median, 75; IQR, 25 to 203 cells/mm^3^ vs. median, 279.5; IQR, 169 to 420 cells/mm^3^, *p* \< 0.01), and also had a lower CD4 T cell count at enrollment (median, 240; IQR, 111 to 395 cells/mm^3^ vs. median, 388; IQR, 254 to 560 cells/mm^3^, *p* \< 0.01). The patients with ODs were more likely to be current smokers (*p* \< 0.01), consume alcohol (*p* \< 0.01), and have prior TB (*p* \< 0.01) than those without ODs.

In the univariate analysis, older age (OR, 0.98; *p* \< 0.01), a lower CD4 T cell count at the time of HIV diagnosis (OR, 1.01; *p* \< 0.01), a lower CD4 T cell count at cohort study enrollment (OR, 1.01; *p* \< 0.01), antiretroviral therapy (OR, 2.47; *p* \< 0.01), current smoking (OR, 2.22; *p* = 0.001), current alcohol consumption (OR, 2.68; *p* \< 0.01), and a history of TB treatment (OR, 5.61; *p* \< 0.01) were associated with ODs among HIV-infected patients ([Table 3](#t3-kjim-2014-322){ref-type="table"}). The multivariate analysis showed that a low CD4 T cell count at the time of HIV diagnosis (OR, 1.01; *p* \< 0.01), current smoking (OR, 2.27; *p* = 0.01), current alcohol consumption (OR, 2.57; *p* = 0.04), and a history of TB (OR, 5.23; *p* \< 0.01) were independent risk factors for ODs.

Outcomes
--------

During the follow-up period, 26 patients (2.4%) died. The ODs-related mortality was 0.7% (n = 8), accounting for 33.3% of deaths. The causes of OD-related death were pneumonia of unknown origin (n = 4), TB (n = 1), *P. jirovecii* pneumonia (n = 1), and *P. jirovecii* pneumonia combined with TB (n = 1).

DISCUSSION
==========

Before the introduction of combination antiretroviral therapy, ODs were the main cause of death in HIV-infected patients. However, advances in antiviral treatment led to a dramatic decline in ODs \[[@b2-kjim-2014-322],[@b8-kjim-2014-322],[@b9-kjim-2014-322]\]. In our study, although 24.4% of the HIV-infected patients developed ODs, they were not the main cause of death, unlike previous studies.

In our series, the most prevalent OD was candidiasis, followed by TB and *P. jirovecii* pneumonia. In a study of 173 HIV-infected patients performed from 1985 to 1998, TB was the most frequent opportunistic infection (25% of patients), followed by candidiasis and herpes zoster \[[@b5-kjim-2014-322]\]. In another study of 176 HIV-infected patients from 1985 to 2000, candidiasis was the most prevalent OD, followed by *P. jirovecii* pneumonia and TB \[[@b4-kjim-2014-322]\]. Based on our data, TB can be considered a re-emerging OD in the HIV population in Korea. The prevalence of ODs in HIV patients varies by location and is 32.5% in China and 27.4% in Ethiopia and New York city \[[@b10-kjim-2014-322]-[@b12-kjim-2014-322]\]. In developing countries, TB remains the most common cause of death among HIV-infected patients, similar to the situation in Korea, and unlike countries with low risks of TB \[[@b13-kjim-2014-322],[@b14-kjim-2014-322]\]. In Korea, the estimated TB incidence in 2012 was 108 per 100,000 population, the highest among Organization for Economic Cooperation and Development countries. The identification and treatment of latent TB infection has lowered the incidence of TB in developed countries. The current guidelines for the management of TB in Korea recommend treating latent TB in HIV-infected patients \[[@b7-kjim-2014-322]\]. Until now, many doctors in Korea have tended to avoid giving TB treatment for latent TB for several reasons: toxicity, drug interactions, and concern about drug resistance. In addition, our data showed that TB developed in patients with a low CD4 T cell count, and many studies demonstrated that impaired cellular immunity was associated with TB reactivation \[[@b15-kjim-2014-322],[@b16-kjim-2014-322]\]. After the guidelines for latent TB are applied to clinical practice in Korea, further studies must examine the effect on the incidence of TB. In our series, a history of TB was associated with ODs among HIV-infected patients. Several studies have also demonstrated that a history of TB was usually associated with TB infection \[[@b17-kjim-2014-322],[@b18-kjim-2014-322]\]. In intermediate TB endemic areas, TB reactivation is more common in HIV-infected patients than *de novo* TB. There were two cases of nontuberculous *Mycobacteria* infection in our study. Our study used the patient data at the time of enrollment, and further studies will examine prospectively collected cohort data.

Our study found a low prevalence of Kaposi's sarcoma and toxoplasmosis compared with other countries. This is because of the geographic variation in Kaposi's sarcoma. de Sanjose et al. \[[@b19-kjim-2014-322]\] reported that the prevalence of Kaposi's sarcoma-associated herpesvirus in the general female population in Korea was only 4.93%.

The associated risk factors for ODs in our study were a low CD4 T cell count at the time of HIV diagnosis, smoking, alcohol consumption, and a history of TB. A low CD4 T cell count is associated with the development of ODs \[[@b10-kjim-2014-322],[@b20-kjim-2014-322]\]. A study of homeless HIV/AIDS patients in Korea showed that they are at an advanced stage at admission, which leads to ODs and an unfavorable outcome \[[@b21-kjim-2014-322]\]. Our results showed that 97% of HIV-infected patients with *P. jirovecii* pneumonia had CD4 T cell counts less than 200 cells/mm^3^; this supports recent guidelines that patients with such low CD4+ T cell counts should receive prophylaxis for *P. jirovecii*. Smoking could influence inflammatory and immune responses in the oral cavity, and smoking was associated with oral candidiasis in some studies \[[@b22-kjim-2014-322],[@b23-kjim-2014-322]\].

This study had several limitations. First, we included only patient data at study enrollment; prospective longitudinal data will provide more accurate data on OD incidence and change in ODs in Korea. Second, we did not calculate the risk factors for ODs for each disease, and did not describe the clinical course of each OD. Third, we included only the data from patients in our cohort study. However, this study enrolled patients from multiple centers that covered most areas of Korea, so it is likely to be representative epidemiological data for Korea.

In conclusion, there was a range of ODs among HIV-infected patients in Korea, the most prevalent being candidiasis, *M. tuberculosis* infection, *P. jirovecii* pneumonia, CMV infection, and herpes zoster, while toxoplasmosis and HIV-related malignancy, such as Kaposi's sarcoma, were rare. A major predictor of OD was a low CD4 T cell count at the time of HIV diagnosis. Based on our data, strategies to diagnose HIV at an early stage of infection, and timely antiretroviral therapy, are needed to reduce ODs among HIV-infected patients in Korea.

KEY MESSAGE
===========

1\. Candidiasis, *Mycobacterium tuberculosis* infection, *Pneumocystis jirovecii* pneumonia, cytomegalovirus infection, and herpes zoster were common opportunistic diseases among Korean human immunodeficiency virus (HIV)-infected patients.

2\. Toxoplasmosis and HIV-related malignancy, such as lymphoma, Kaposi's sarcoma, and cervical carcinoma, were rare in Korea.

3\. A major predictor of opportunistic diseases was a low CD4 T cell count at the time of HIV diagnosis.
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###### 

Comparisons of demographic characteristics between patients with ODs and without ODs

  Characteristic                               Total (n = 1,086)                                           ODs (+) (n = 297)                                           ODs (--) (n = 789)                                          *p* value
  -------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------
  Age, yr                                      41 (33--50)                                                 44 (36--52)                                                 41 (32--50)                                                 \< 0.01
  Male sex                                     1,007 (92.7)                                                279 (93.9)                                                  728 (92.3)                                                  0.37
  Transmission route                                                                                                                                                                                                               
   Sexual contact                              945 (97.0)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^   261 (87.8)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^   684 (86.7)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^   0.89
   Transfusion or blood product                24 (2.5)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^     9 (3.0)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^      15 (1.9)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^     0.87
   Injection drug use                          5 (0.5)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^      3 (1.0)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^      2 (0.3)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^      0.09
   Vertical transmission                       0                                                           0                                                           0                                                           \-
  CD4 T cell count at enrollment, cell/mm^3^   352 (207--514)                                              240 (111--395)                                              388 (254--560)                                              \< 0.01
  CD4 T cell at HIV diagnosis, cell/mm^3^      237 (93--377)                                               75 (25--203)                                                279.5 (169--420)                                            \< 0.01
  Viral load at enrollment, log copies/mL      5.69 (3.88--6.24)                                           5.04 (4.17--5.56)                                           4.57 (3.8--6.09)                                            0.62
  HARRT at enrollment                          730 (67.3)                                                  232 (78.1)                                                  498 (63.1)                                                  \< 0.01
  Body mass index, kg/m^2^                     21.5 (19.4--23.5)                                           21.1 (19--23.5)                                             21.6 (19.8--23.6)                                           0.77
  Smoking                                                                                                                                                                                                                          
   Current                                     465 (71.5)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^   111 (59.4)                                                  354 (76.5)                                                  \< 0.01
   Former                                      648 (68.0)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^   189 (70.0)                                                  459 (67.2)                                                  0.40
  Alcohol                                                                                                                                                                                                                          
   Current                                     483 (73.0)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^   106 (57.9)                                                  377 (78.7)                                                  \< 0.01
   Former                                      656 (70.0)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^   183 (68.3)                                                  473 (70.0)                                                  0.47
  Tuberculosis history                         196 (18.0)                                                  115 (38.7)                                                  81 (10.2)                                                   \< 0.01
  Hypertension                                 112 (10.3)                                                  29 (9.7)                                                    83 (10.5)                                                   0.84
  Diabetes mellitus                            71 (6.5)                                                    17 (5.7)                                                    54 (6.8)                                                    0.38
  Previous BCG history                         377 (54.5)^[a](#tfn1-kjim-2014-322){ref-type="table-fn"}^   108 (36.4)                                                  269 (34.1)                                                  0.71

Values are presented as median (interquartile range) or number (%).

OD, opportunistic disease; HIV, human immunodeficiency; HARRT, highly active antiretroviral therapy; BCG, Bacillus Calmette-Guérin.

This data included only on that complete a questionnaire.

###### 

Distribution of opportunistic disease and CD4 T cell count

  Variable                                     No. of cases   CD4 T cell, cell/mm^3^
  -------------------------------------------- -------------- ------------------------
  Candidiasis                                  176 (16.2)     
   Oral candidiasis                            120            49 (17--133)
   Esophageal candidiasis                      54             43 (19--95.5)
   Respiratory candidiasis                     2              \-
  Tuberculosis                                 120 (11.0)     87 (37--205)
  Nontuberculous Mycobacteria infection        2 (0.2)        \-
  *Pneumocystis jirovecii* pneumonia           121 (11.1)     30 (11--68)
  CMV infection                                52 (4.7)       25.5 (12.75--101.5)
   Retinitis                                   19             
   Pneumonia                                   13             
   Hepatitis                                   9              
   Colitis                                     2              
   Cytomegalovirus viremia                     9              
  Herpes zoster                                44 (4.0)       185 (116.5--273.5)
  Herpes simplex virus infection               8 (0.7)        128 (10--320)
  Recurrent pneumonia                          7 (0.7)        62.5 (12--170)
  Progressive multifocal leukoencephalopathy   6 (0.6)        107 (64.25--154)
  Cryptococcosis                               6 (0.6)        31.2 (9.5--76.75)
  Toxoplasmosis                                4 (0.4)        107 (25.5--246.25)
  Isosporiasis                                 1 (0.09)       \-
  Non-Hodgkin's lymphoma                       4 (0.4)        128 (26--222.5)
   Burkitt lymphoma                            1              
   Diffuse large B-cell lymphoma               3              
  Kaposi's sarcoma                             8 (0.7)        133 (28--269)
  Cervical carcinoma                           1 (0.09)       \-

Values are presented as number (%) or median (interquartile range).

###### 

Risk factors for opportunistic disease among HIV patients

  Factor                      Univariate analysis   Multivariate analysis                                  
  --------------------------- --------------------- ----------------------- --------- ------- ------------ ---------
  Age                         0.98                  0.96--0.99              \< 0.01   0.98    0.95--1.01   0.29
  Body mass index             1.01                  0.98--1.02              0.77                           
  CD4 T cell, HIV diagnosis   1.01                  1.01--1.05              \< 0.01   1.01    1.03--1.07   \< 0.01
  Viral load at enrollment    1                     0.90--1.02              0.67                           
  CD4 T cell at enrollment    1.01                  1.02--1.04              \< 0.01   1.001   1.01--1.03   0.45
  HAART at enrollment         2.47                  1.79--3.41              \< 0.01   1.41    0.55--3.56   0.47
  Current smoking             2.22                  1.55--3.19              \< 0.01   2.27    1.22--4.26   0.01
  Current alcohol             2.68                  1.86--3.87              \< 0.01   2.57    1.34--4.91   0.04
  Tuberculosis history        5.61                  4.03--7.7               \< 0.01   5.23    2.69--10.2   \< 0.01

HIV, human immunodeficiency; OR, odds ratio; CI, confidence interval; HAART, highly active antiretroviral therapy.
